The pretreatment RNA levels of Bim predicted the ability of EGFR, HER2 and PI3K inhibitors to induce apoptosis in EGFR-mutant, HER2-amplified and PIK3CA-mutant cancer cells, respectively, while Bim levels did not predict responsiveness to standard chemotherapies such as gemcitabine and cisplatin [618]. This evidence concerns the gene PIK3CA and cancer.